2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
22
Neoplasms
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Recurrence
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Cancer
4
Uveal Melanoma
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Interventions
fludarabine phosphate
29
Etoposide
26
pegaspargase
24
Peripheral Blood Stem Cell Transplantation
23
Cyclophosphamide
23
Whole-Body Irradiation
21
Mycophenolic Acid
21
Gemcitabine
19
Busulfan
19
Methotrexate
16
Dexamethasone
16
Tacrolimus
15
Cyclosporine
14
Antilymphocyte Serum
13
Radiotherapy
12
Oxaliplatin
10
Rituximab
9
Melphalan
8
Asparaginase
8
Doxorubicin
7
Bortezomib
7
spartalizumab
6
Vorinostat
6
Lenalidomide
6
Flow Cytometry
6
tislelizumab
5
Vincristine
5
Therapeutics
5
Methylprednisolone
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Extranodal NK-T-Cell
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled